On Thursday, Shares of Great Basin Scientific, Inc. (NASDAQ:GBSN), surged 8.67% to $0.0940.
Great Basin Scientific, declared it added 28 new customers in the third quarter of 2015. As of September 30th, the company had secured 143 U.S. customers and had 64 evaluations either in-progress or planned, contrast to 115 customers and 46 evaluations stated for the second quarter ending June 30, 2015, representing an improvement of 24 percent and 39 percent respectively. Great Basin’s sales funnel, which represents the number of customers together with active and planned customer evaluations, grew to 207 at the end of the third quarter, up from 161 at the end of the second quarter, an improvement of 28.5 percent.
Adoption for Great Basin’s Group B Streptococcus (GBS) test—which was commercially launched on June 1, 2015—continued to expand. The Company ended the third quarter with 66 customers and potential customers either evaluating or planned to evaluate GBS, a 38.6 percent improvement over the customer and potential customer sites for GBS stated at the end of second quarter.
“September was the strongest month for customer acquisition in the history of Great Basin—with 24 new customers added in that month alone—showing what we believe is sustained strength in our sales funnel, and ongoing demand for our Group B Strep test,” said Ryan Ashton, co-founder and Chief Executive Officer of Great Basin Scientific. “I’m extremely happy with the strides we have made toward a shortened sales cycle and for achieving a 91 percent evaluation win-rate in the quarter, which adds to our confidence of achieving our customer acquisition guidance by the end of the year.”
Great Basin Scientific, Inc., a molecular diagnostic testing company, doing business as Great Basin Corporation, develops and commercializes molecular diagnostic systems that are designed to test hospital-attained infections. The company’s platform provides C. diff test, a rapid medical diagnostic test for the detection of C. diff, a gram-positive bacteria that causes severe diarrhea and other intestinal disorders. It also provides Group B streptococcus test, which is used to detect Group B streptococcus from an anal/vaginal swab of a pregnant woman.
On other hand, Shares of Aeterna Zentaris Inc. (NASDAQ:AEZS), declined -2.44% to $0.07.
Aeterna Zentaris, is -94.96% down from its peak. The consensus price target is $1.23. The stock was trading at $0.07, up 36 percent from 52-week low of $0.05. its average volume stood at 20.13M. the stock has shown 17.02% volatility for the week, while for the month it was 23.66%.
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women’s health. The Company has three wholly owned direct and indirect auxiliaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned partner of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc.
